Evidence map›Paper›PMID 41053843›Full record

ArticleJournal of cannabis research2025

Efficacy of non-psychotropic Cannabis sativa L. standardized extracts in a model of intestinal inflammation.

Nicole Maranta, Giulia Martinelli, Marco Fumagalli, Carola Pozzoli, Elisa Sonzogni, Nora Rossini, Umberto Ciriello, Giuseppe Paladino, Mario Dell'Agli, Stefano Piazza and 1 more

Abstract read
In one paragraph

Article in Journal of cannabis research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Nicole MarantaUniversità degli Studi di Milano, Milan, Italy.
Giulia MartinelliUniversità degli Studi di Milano, Milan, Italy.
Marco FumagalliUniversità degli Studi di Milano, Milan, Italy.
Carola PozzoliUniversità degli Studi di Milano, Milan, Italy.
Elisa SonzogniUniversità degli Studi di Milano, Milan, Italy.
Nora RossiniLinnea SA, Riazzino, Switzerland.
Umberto CirielloLinnea SA, Riazzino, Switzerland.
Giuseppe PaladinoLinnea SA, Riazzino, Switzerland.
Mario Dell'AgliUniversità degli Studi di Milano, Milan, Italy.
Stefano PiazzaUniversità degli Studi di Milano, Milan, Italy. Stefano.piazza@unimi.it.
Enrico SangiovanniUniversità degli Studi di Milano, Milan, Italy.

Funding

Linnea SA not applicableMinistero dell'Università e della Ricerca not applicable
6 · The paper itself

Abstract

backgroundThe use of Cannabis sativa L. (Cannabis) was reported by observational studies on inflammatory bowel diseases (IBD) patients. However, this indication is poorly supported by clinical trials. Several pre-clinical studies demonstrated the anti-inflammatory activity of Δ⁹-tetrahydrocannabinol (Δ⁹-THC) and cannabidiol (CBD) at intestinal level. On the contrary, minor cannabinoids, such as cannabigerol (CBG), were less investigated. Moreover, several authors suggested that complex Cannabis extracts might display a higher efficacy in respect to pure cannabinoids against inflammatory disorders.

methodsThis study was aimed at investigating the role of Cannabis extracts, standardized in CBD and CBG content, in a model of in vitro-induced intestinal inflammation using CaCo-2 cells. Inflammatory mediators at transcriptional (PCR arrays) and protein level (ELISA assays) were investigated and correlated with enterocyte layer permeability. The two evaluated extracts, A and B, come from the mix of the same Cannabis varieties (Cannabis sativa L. Chemotype III and Chemotype IV), and are standardized in CBD and CBG at the same level, by changing the polarity of the primary extraction solvents.

resultsPro-inflammatory cytokines involved in IBD, such as IL-1β and IFN-γ, induced the expression and the release of chemokines for lymphocytes (CXCL-9, CXCL-10, CCL20) in CaCo-2, while Cannabis extracts (100 µg/mL) or individual compounds (8 µM) showed inhibitory activity. After simulated digestion, extract A abrogated the release of CCL-20, while extract B abrogated the release of CXCL-9 and CXCL-10. The inhibition of CXCL-9 was demonstrated at transcriptional level also. The inhibitory activity paralleled with the content of CBD or CBG, acting at least in part through NF-κB impairment (-42% and - 66%, respectively). However, Cannabis extracts showed greater effect in the CaCo-2-THP-1 co-culture inflammation model compared to individual cannabinoids, thus partially recovering the epithelial barrier measured by transepithelial electrical resistance (TEER), and zonula occludens (ZO-1) expression.

conclusionsData collected within this study showed the importance of standardization and extraction method reproducibility through manufacturing and process control, besides demanding future investigations focusing on the effect of Cannabis extracts against intestinal inflammation, which show in this context effects higher than individual cannabinoids.

Indexed as

CannabisCBGGut inflammationIBD CBD

Identifiers

PMID41053843
PMCPMC12502145

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.